Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
ApexOnco Front Page
Recent articles
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company will license EGFR and cMet inhibitors from Celyn.
After several discontinuations, a new ADC enters the clinic.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Median PFS appears to back earlier response rate promise.
